NIMU NIMS' Motion Platform Pre- and Post-Treatments Beneficial in Experimental Cardiac Arrest

NIMS' Motion Platform Pre- and Post-Treatments Beneficial in Experimental Cardiac ArrestBusiness Wire "US Press Releases "
NORTH BAY VILLAGE, Fla.--(BUSINESS WIRE)--
Gary Macleod, Chief Executive Officer, Non-Invasive Monitoring Systems, Inc. (NIMS) (OTCBB:NIMU) announced that Drs Jose A. Adams, Jorge Bassuk and associates from Mt. Sinai Medical Center of Greater Miami presented two papers at the annual meeting of the American Heart Association (AHA) in Orlando, FL on November 7 to 11. These papers dealt with NIMS' patented, prototype CPR motion platform device that produces whole body periodic acceleration (WBPA).
In the first of these two presentations, Dr. Adams and associates either pre-treated (also known as preconditioned) one group of large animals with WBPA for 1 hour and another group without preconditioning. They then induced stoppage of the heart for about 18 minutes while standard closed chest CPR was applied. The cardiac rhythm was then electrically restored. After restoration, the animals that were preconditioned had less cardiac rhythm disturbances and better heart function than the animals that were not. They concluded that WBPA preconditions the heart to deprivation of cardiac blood flow thereby providing cardiac protection.
In the second presentation, Dr. Adams and associates immediately induced heart stoppage for about 18 minutes while standard closed chest CPR was applied. After electrical restoration of cardiac rhythm, one group of animals received 2 hours of WBPA and the other did not. The animals that were post-conditioned with WBPA had better heart function than the animals that were not post-conditioned. They concluded that WBPA post-conditions the heart to deprivation of cardiac blood flow thereby providing cardiac protection.
Dr. Jose A. Adams attributed these beneficial effects "to the release of nitric oxide and prostacylin into the circulation promoted by WBPA preceding and following heart stoppage that pre-conditions and post-conditions the heart and other organs, respectively, to minimize the known adverse effects of damage caused after circulation is re-established, a phenomenon called ischemia/reperfusion (I/R) injury." He added that "I/R can also occur after treatment of acute blood loss and sepsis, and, following heart attacks and strokes." He recommended that "since WBPA is safe, non-invasive and drug-free, it should be tested for benefits of post-conditioning in a clinical trial."
Dr. Marvin Sackner, Chairman of the Board of Directors stated that the WBPA device for human, non-CPR use is called "Exer-Rest(TM)," which is a platform that repetitively moves a supine person lying on a mattress in a head to foot direction at about 140 times a minute with a displacement of 3/4 inch or less over a period of 30 to 45 minutes. A clinical trial is currently underway to support the intended use of "Exer-Rest(TM)" for temporary relief of musculoskeletal pain associated with osteoarthritis of the hips in order to meet FDA approval for its marketing in the United States.
Dr. Sackner added that NIMS has recently relocated its offices to the IVAX building in Miami and is in the process of launching a new web site.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
Source: Non-Invasive Monitoring Systems, Inc.